Press release Biocartis Group NV: Biocartis Announces

PRESS RELEASE: REGULATED INFORMATION 

28 October 2022, 07:01 CEST

Biocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting Securities

Mechelen, Belgium, 28 October 2022 – Biocartis Group NV (the “Company” or “Biocartis”), an progressive molecular diagnostics firm (Euronext Brussels: BCART), immediately pronounces that following the primary drawdown by the Company below the brand new senior secured convertible time period mortgage (“Convertible Term Loan”) concluded with sure funds and accounts managed or suggested by Highbridge Capital Management LLC (“Highbridge”) and sure funds managed or suggested by Whitebox Advisors LLC (“Whitebox”, and along with Highbridge, the “Lenders”) introduced on 20 October 2022, a primary portion of the receivables due by the Company to Highbridge below the Convertible Term Loan in an quantity of EUR 60,509.79 (consisting of principal quantity, curiosity and redemption quantity) was contributed in form by Highbridge in opposition to the issuance of 60,559 new shares of the Company at a problem value of ca. EUR 0.99918 per share.

In view hereof, and in accordance with article 15 of the Belgian Act of two May 2007 on the disclosure of main shareholdings in issuers of which shares are admitted to buying and selling on a regulated market and laying down miscellaneous provisions, the excellent share capital and excellent voting securities of the Company might be summarized as follows:

• Total excellent share capital: EUR 584,169.56;
• Total excellent voting securities: 58,416,956;
• Total excellent voting rights: 58,416,956;
• Shares that may nonetheless be issued upon train of subscription rights: 2,248,458 shares (every share entailing one voting proper), of which:
  • 150,896 shares might be issued upon the train of 150,896 excellent share choices (every share possibility having the type of a subscription proper) which are nonetheless excellent below the ‘2013 Plan’ for workers, consultants and administration members of the Company, entitling the holders thereof to amass one new share per possibility;
  • 140,064 shares might be issued upon the train of 140,064 excellent share choices (every share possibility having the type of a subscription proper) which are nonetheless excellent below the ‘2015 Plan’ for workers, consultants, administration members and administrators of the Company, entitling the holders thereof to amass one new share per possibility;
  • 470,836 shares might be issued upon the train of 470,836 excellent share choices (every share possibility having the type of a subscription proper) which are nonetheless excellent below the ‘2018 Plan’ for (primarily) sure chosen workers of the Company and its subsidiaries, in addition to for consultants of the Company and its subsidiaries, unbiased administrators of the Company and administrators of the Company’s subsidiaries, entitling the holders thereof to amass one new share per possibility;
  • 626,662 shares might be issued upon the train of 626,662 excellent share choices (every share possibility having the type of a subscription proper) which are nonetheless excellent below the ‘2020 Plan’ for members of the personnel of the Company and/or its subsidiaries, entitling the holders thereof to amass one new share per possibility; and
  • 860,000 shares might be issued upon the train of 860,000 excellent share choices (every share possibility having the type of a subscription proper) which are nonetheless excellent below the ‘2020B Plan’ for members of the manager administration of the Company, entitling the holders thereof to amass one new share per possibility.

In addition, quite a few shares are issuable pursuant to the phrases of (i) the abovementioned Convertible Term Loan, (ii) sure excellent 4.00% convertible bonds initially due 2024/2027, and (iii) sure excellent 4.50% convertible bonds initially due 2024/2026.

Going ahead, the Company will problem a press release on the finish of every month with an replace on additional conversions and excellent voting securities.

— END —

More data:
Renate Degrave
Head of Corporate Communications & Investor Relations Biocartis
e-mail        [email protected]
tel            +32 15 631 729
cellular      +32 471 53 60 64

About Biocartis

With its revolutionary and proprietary Idylla™ platform, Biocartis (Euronext Brussels: BCART) aspires to allow personalised medication for sufferers around the globe by way of common entry to molecular testing, by making molecular testing actionable, handy, quick and appropriate for any lab. The Idylla™ platform is a totally automated sample-to-result, real-time PCR (Polymerase Chain Reaction) primarily based system designed to supply in-house entry to correct molecular data in a minimal period of time for sooner, knowledgeable remedy selections. Idylla™’s repeatedly increasing menu of molecular diagnostic checks handle key unmet scientific wants, with a spotlight in oncology. This is the quickest rising section of the molecular diagnostics market worldwide. Today, Biocartis presents checks supporting melanoma, colorectal, lung and liver most cancers, in addition to for COVID-19, Flu, RSV and sepsis. For extra data, go to www.biocartis.com or observe Biocartis on Twitter @Biocartis_ , Facebook or LinkedIn. 

Biocartis and Idylla™ are registered emblems in Europe, the United States and different international locations. The Biocartis and Idylla™ trademark and brand are used emblems owned by Biocartis. Please discuss with the product labeling for relevant supposed makes use of for every particular person Biocartis product.
This press release just isn’t for distribution, instantly or not directly, in any jurisdiction the place to take action could be illegal. Any individuals studying this press release ought to inform themselves of and observe any such restrictions. Biocartis takes no accountability for any violation of any such restrictions by any individual. This press release doesn’t represent a proposal or invitation for the sale or buy of securities in any jurisdiction. No securities of Biocartis could also be provided or bought within the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration below the U.S. Securities Act of 1933, as amended.

Forward-looking statements
Certain statements, beliefs and opinions on this press release are forward-looking, which mirror the Company’s or, as acceptable, the Company administrators’ or managements’ present expectations and projections regarding future occasions such because the Company’s outcomes of operations, monetary situation, liquidity, efficiency, prospects, development, methods and the business by which the Company operates. By their nature, forward-looking statements contain quite a few dangers, uncertainties, assumptions and different components that would trigger precise outcomes or occasions to vary materially from these expressed or implied by the forward-looking statements. These dangers, uncertainties, assumptions and components might adversely have an effect on the end result and monetary results of the plans and occasions described herein. A mess of things together with, however not restricted to, modifications in demand, competitors and know-how, may cause precise occasions, efficiency or outcomes to vary considerably from any anticipated growth. Forward-looking statements contained on this press release concerning previous developments or actions will not be ensures of future efficiency and shouldn’t be taken as a illustration that such developments or actions will proceed sooner or later. In addition, even when precise outcomes or developments are in keeping with the forward-looking statements contained on this press release, these outcomes or developments will not be indicative of outcomes or developments in future intervals. No representations and warranties are made as to the accuracy or equity of such forward-looking statements. As a consequence, the Company expressly disclaims any obligation or enterprise to release any updates or revisions to any forward-looking statements on this press release on account of any change in expectations or any change in occasions, situations, assumptions or circumstances on which these forward-looking statements are primarily based, besides if particularly required to take action by legislation or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such individual’s officers or workers ensures that the assumptions underlying such forward-looking statements are free from errors nor does both settle for any accountability for the longer term accuracy of the forward-looking statements contained on this press release or the precise prevalence of the forecasted developments. You mustn’t place undue reliance on forward-looking statements, which converse solely as of the date of this press release.